Adagrasib (KRAZATI): AN NCCN CATEGORY 2A RECOMMENDED OPTION IN THE NCCN CLINICAL PRACTICE GUIDELINES IN ONCOLOGY (NCCN GUIDELINES®) FOR CNS CANCERS: KRAS G12C NSCLC WITH BRAIN METASTASES1,2
CNS=central nervous system; NCCN=National Comprehensive Cancer Network; NSCLC=non-small cell lung cancer.
Adagrasib (KRAZATI) is included as a treatment option for NSCLC in the NCCN Guidelines®1
NCCN Category 2A Recommended
NSCLC
NCCN Guidelines recommend adagrasib (KRAZATI) as a subsequent therapy option for patients with KRAS G12C–mutated advanced NSCLC after progression (Category 2A).1
Adagrasib (KRAZATI) is included as a treatment option for NSCLC CNS metastases in the NCCN Guidelines for CNS Cancers2
NCCN Category 2A Recommended
CNS Cancers: KRAS G12C NSCLC with brain metastases
NCCN Guidelines for CNS cancers recommend adagrasib (KRAZATI) as a systemic therapy option for patients with KRAS G12C–mutated advanced NSCLC with brain metastases (Category 2A).2
NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.
References:
- Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Non-Small Cell Lung Cancer V.3.2025. © National Comprehensive Cancer Network, Inc. 2025. All rights reserved. Accessed February 6, 2025. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.
- Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Central Nervous System Cancers V.4.2024. © National Comprehensive Cancer Network, Inc. 2025. All rights reserved. Accessed February 6, 2025. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.